We are live on ! Find out more
VC

Vivo Capital Portfolio holdings

AUM $1.2B
1-Year Est. Return 911.44%
This Fund
S&P 500
This Quarter Est. Return
+75.05%
1 Year Est. Return
+911.44%
3 Year Est. Return
+7,373.93%
5 Year Est. Return
+10,475.15%
10 Year Est. Return
+136,503.27%
AUM
$1.24B
AUM Growth
+$266M
Cap. Flow
+$14.8M
Cap. Flow %
1.19%
Top 10 Hldgs %
58%
Holding
50
New
8
Increased
10
Reduced
2
Closed
3

Top Buys

Rank Stock Value
1
SABS icon
SAB Biotherapeutics
SABS
+$25.8M
2
ABVX
Abivax
ABVX
+$22M
3
COGT icon
Cogent Biosciences
COGT
+$19.7M
4
DYN icon
Dyne Therapeutics
DYN
+$17.1M
5
LBRX
LB Pharmaceuticals
LBRX
+$12.7M

Top Sells

Rank Stock Value
1
SLNO
Soleno Therapeutics
SLNO
+$125M
2
CMPS
Compass Pathways
CMPS
+$9.41M
3
IOBT
IO Biotech
IOBT
+$8.58M
4
CELC icon
Celcuity
CELC
+$8.15M
5
CTMX icon
CytomX Therapeutics
CTMX
+$6.5M

Sector Composition

Rank Sector Weight
1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
DNTH icon
26
Dianthus Therapeutics
DNTH
$5.95B
$13.9M 1.12%
+353,998
New +$9.05M
LBRX
27
LB Pharmaceuticals
LBRX
$1.3B
$12.6M 1.02%
+800,000
New +$12.7M
CAMP icon
28
CAMP4 Therapeutics
CAMP
$212M
$11.8M 0.95%
+3,921,568
New +$7.26M
ATXS
29
DELISTED
Astria Therapeutics
ATXS
$11.3M 0.91%
1,552,685
– –
PEPG icon
30
PepGen
PEPG
$132M
$10.7M 0.86%
+2,325,000
New +$3.75M
DBVT
31
DBV Technologies
DBVT
$842M
$10.5M 0.85%
1,054,506
– –
PRAX icon
32
Praxis Precision Medicines
PRAX
$8.68B
$10.5M 0.85%
198,895
+31,295
+19% +$1.52M
ABEO icon
33
Abeona Therapeutics
ABEO
$382M
$9.73M 0.78%
1,842,751
– –
CTMX icon
34
CytomX Therapeutics
CTMX
$716M
$9.2M 0.74%
2,884,615
-2,884,615
-50% -$6.5M
EPRX
35
Eupraxia Pharmaceuticals
EPRX
$421M
$7.96M 0.64%
+1,350,000
New +$7.35M
UNCY icon
36
Unicycive Therapeutics
UNCY
$144M
$7.8M 0.63%
1,789,916
+652,901
+57% +$2.85M
MNPR icon
37
Monopar Therapeutics
MNPR
$795M
$7.39M 0.59%
+90,500
New +$4.05M
TNGX icon
38
Tango Therapeutics
TNGX
$4.7B
$6.52M 0.53%
776,699
+176,699
+29% +$1.2M
DCTH icon
39
Delcath Systems
DCTH
$443M
$6.12M 0.49%
569,526
– –
SLN
40
Silence Therapeutics
SLN
$524M
$5.74M 0.46%
1,105,454
– –
ETNB
41
DELISTED
89bio
ETNB
$5.54M 0.45%
376,804
– –
TIL icon
42
Instil Bio
TIL
$48.4M
$5.23M 0.42%
292,743
– –
SERA icon
43
Sera Prognostics
SERA
$76M
$5.05M 0.41%
1,650,440
– –
SRZN icon
44
Surrozen
SRZN
$248M
$3.35M 0.27%
260,000
– –
TENX icon
45
Tenax Therapeutics
TENX
$495M
$1.59M 0.13%
208,333
– –
BOLT icon
46
Bolt Biotherapeutics
BOLT
$7.78M
$937K 0.08%
176,064
– –
DTIL icon
47
Precision BioSciences
DTIL
$193M
$25.8K ﹤0.01%
4,675
– –
CELC icon
48
Celcuity
CELC
$4.49B
– –
-610,500
Closed -$8.15M
CMPS
49
Compass Pathways
CMPS
$1.76B
– –
-3,362,385
Closed -$9.41M
IOBT
50
DELISTED
IO Biotech
IOBT
– –
-6,173,439
Closed -$8.58M
1
2

Similar funds

SGDR
SPX Gestao de Recursos Rio De Janeiro, Brazil $1.2B AUM 59.05% 1-Year Est. Return
FCCPG
FountainVest China Capital Partners GP3 Grand Cayman, Cayman Islands $1.2B AUM 6.95% 1-Year Est. Return
AIM
Anchor Investment Management Columbia, South Carolina $1.2B AUM 17.33% 1-Year Est. Return
SC
Shay Capital New York $1.2B AUM 37.47% 1-Year Est. Return
MB
MidFirst Bank Oklahoma City, Oklahoma $1.21B AUM
CCM
Condor Capital Management Martinsville, New Jersey $1.2B AUM 13.18% 1-Year Est. Return
LWIC
Leith Wheeler Investment Counsel Vancouver, British Columbia, Canada $1.21B AUM 12.04% 1-Year Est. Return
TIM
Tortoise Investment Management White Plains, New York $1.21B AUM 13.04% 1-Year Est. Return

Vivo Capital's Q3 2025 Portfolio in Review

As of Q3 2025, Vivo Capital held 50 positions worth $1.24B, up 27% from $977M the previous quarter. Its ten largest holdings account for 58% of the portfolio.

Vivo Capital's Q3 2025 filing shows 8 new, 10 increased, 2 reduced and 3 closed positions. Its largest new stake was SAB Biotherapeutics: 11,420,000 shares worth $23M. The largest sale was Soleno Therapeutics, an estimated $125M.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, unchanged from a quarter earlier.

  • Vivo Capital's largest Q3 2025 buy was SAB Biotherapeutics: 11,420,000 shares worth $23M.
  • Vivo Capital added most to Cogent Biosciences in Q3 2025, an estimated $19.7M increase.
  • Vivo Capital's biggest Q3 2025 reduction was Soleno Therapeutics, cutting an estimated $125M.
  • Vivo Capital fully exited Compass Pathways in Q3 2025, selling an estimated $9.41M.
  • Vivo Capital's ten largest holdings make up 58% of its $1.24B portfolio in Q3 2025.
  • Vivo Capital opened 8 new positions and closed 3 in Q3 2025.
  • Vivo Capital's portfolio value rose 27% quarter-over-quarter to $1.24B.

Based on Vivo Capital's 13F filing for Q3 2025, filed 14 Nov 2025.